We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+2.69%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$8.16B
AUM Growth
+$296M
Cap. Flow
-$1.61B
Cap. Flow %
-19.71%
Top 10 Hldgs %
74.41%
Holding
114
New
7
Increased
22
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$80.1M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$65.5M
3
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$58.8M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$48.9M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$35.8M

Top Sells

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$84.5M
2
CHTP
CHELSEA THERAPEUTICS INT'L LTD
CHTP
+$37.3M
3
HALO icon
Halozyme
HALO
+$24.8M
4
GILD icon
Gilead Sciences
GILD
+$23.4M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 44.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GEVA
1
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$1.12B 13.68%
10,660,432
+12,250
+0.1% +$1.04M
PCYC
2
DELISTED
PHARMACYCLICS INC
PCYC
$860M 10.54%
9,591,546
+853,658
+10% +$80.1M
SGEN
3
DELISTED
Seagen Inc. Common Stock
SGEN
$860M 10.53%
22,472,229
+1,732,803
+8% +$65.5M
INCY icon
4
Incyte
INCY
$25.9B
$838M 10.26%
14,845,559
+10,000
+0.1% +$511K
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$5.08B
$463M 5.67%
20,481,442
– –
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$374M 4.58%
13,654,902
+752
+0% +$20K
ITMN
7
DELISTED
INTERMUNE INC
ITMN
$209M 2.55%
4,722,869
+398,026
+9% +$14.7M
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.44B
$139M 1.7%
10,890,872
+5,023,841
+86% +$48.9M
BMRN icon
9
BioMarin Pharmaceuticals
BMRN
$12.9B
$119M 1.45%
1,908,230
+25,000
+1% +$1.51M
XOMA
10
DELISTED
Xoma
XOMA
$106M 1.3%
1,153,299
+420
+0% +$36.4K
AVNR
11
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$105M 1.28%
18,558,487
+12,768,348
+221% +$58.8M
VNDA icon
12
Vanda Pharmaceuticals
VNDA
$319M
$70.7M 0.87%
4,372,153
-73,543
-2% -$980K
ANAC
13
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$57.6M 0.71%
3,248,043
+152,725
+5% +$2.46M
DYAX
14
DELISTED
DYAX CORPORATION
DYAX
$54.5M 0.67%
5,681,237
+3,149,471
+124% +$24M
RPRX
15
DELISTED
Repros Therapeutics Inc.
RPRX
$48.1M 0.59%
2,778,654
– –
MRTX
16
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$47.6M 0.58%
2,380,074
– –
QCOR
17
DELISTED
QUESTCOR PHARMA INC
QCOR
$46.2M 0.57%
500,000
-217,745
-30% -$18.6M
CERS icon
18
Cerus
CERS
$566M
$42.5M 0.52%
10,246,591
+1,791,285
+21% +$7.67M
DSCI
19
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$40.9M 0.5%
3,537,137
– –
ARAV
20
DELISTED
Aravive, Inc. Common Stock
ARAV
$34.9M 0.43%
+207,648
New +$35.8M
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
$32.8M 0.4%
793,221
+263,231
+50% +$13.6M
HRTX icon
22
Heron Therapeutics
HRTX
$60.4M
$32.1M 0.39%
2,607,784
+440,000
+20% +$5.26M
ACOR
23
DELISTED
Acorda Therapeutics
ACOR
$30.5M 0.37%
7,551
-782
-9% -$3.19M
HALO icon
24
Halozyme
HALO
$12.3B
$27.4M 0.34%
2,776,143
-2,921,996
-51% -$24.8M
GILD icon
25
Gilead Sciences
GILD
$181B
$21.2M 0.26%
256,108
-300,000
-54% -$23.4M
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2014 Portfolio in Review

As of Q2 2014, Julian Baker held 114 positions worth $8.16B, up 3.8% from $7.87B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Julian Baker withdrew a net $1.61B in Q2 2014, closing 9 positions and reducing 9 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $84.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 48% a quarter earlier.

Against the trend, Julian Baker opened a new position in Aravive, Inc. Common Stock worth $34.9M.

  • Julian Baker's largest Q2 2014 buy was Aravive, Inc. Common Stock: 207,648 shares worth $34.9M.
  • Julian Baker added most to PHARMACYCLICS INC in Q2 2014, an estimated $80.1M increase.
  • Julian Baker's biggest Q2 2014 reduction was Halozyme, cutting an estimated $24.8M.
  • Julian Baker fully exited Intercept Pharmaceuticals, Inc. in Q2 2014, selling an estimated $84.5M.
  • Julian Baker's ten largest holdings make up 74% of its $8.16B portfolio in Q2 2014.
  • Julian Baker opened 7 new positions and closed 9 in Q2 2014.
  • Julian Baker's portfolio value rose 3.8% quarter-over-quarter to $8.16B.

Based on Baker Bros. Advisors's 13F filing for Q2 2014, filed 14 Aug 2014.